Kos Appoints John J. Howarth as Vice President of Investor Relations and Corporate Affairs

"We are very excited that Jack is joining our leadership team,"said Adrian Adams, President and CEO of Kos Pharmaceuticals. "He hasall the elements necessary for a successful investor relations leader.His experience gained with Warner-Lambert, Elan and Antigenicsencompasses, among other things, a significant financial background inaccounting, financial analysis, M&A and SEC reporting. All of thiswill ensure timely, clear and seamless communication with all ourstakeholders as we continue to deliver with excellence against ourshort, medium and long-term plans."

Mr. Howarth joins Kos from Antigenics, Inc. where he served asHead of Investor Relations since 2003. Prior to holding this position,he was Vice President of Investor Relations at Elan Corporation, PLCfrom 2000 to 2003. Previously, Mr. Howarth had a career spanningnearly two decades at Warner-Lambert Company where he held positionsof increasing responsibility. During his tenure, Warner-Lambert had anumber of significant corporate and product events including thelaunch of Lipitor(R), the launch and subsequent recall of Rezulin(R),as well as significant merger discussions. Mr. Howarth received hisB.S. degree in Accounting from Boston College and his M.B.A. inFinance from Seton Hall University.

Kos Pharmaceuticals, Inc. is a fully integrated specialtypharmaceutical company engaged in developing, commercializing,manufacturing and marketing proprietary prescription products for thetreatment of chronic diseases. The Company's principal productdevelopment strategy is to reformulate existing pharmaceuticalproducts with large market potential to improve safety, efficacy, orpatient compliance. The Company currently markets Niaspan(R) andAdvicor(R) for the treatment of cholesterol disorders, Azmacort(R) forthe treatment of asthma, Cardizem(R)LA for the treatment ofhypertension and angina, and Teveten(R) and Teveten(R) HCT for thetreatment of hypertension. Kos is developing additional products, hasproprietary drug delivery technologies in solid-dose and aerosolmetered-dose inhalation administration and is pursuing certainstrategic business development and licensing opportunities.

Certain statements in this press release, including statementsregarding the Company's ability to develop or acquire additionalproducts, and the Company's ability to successfully negotiateadditional important strategic business development and licensingopportunities, are forward-looking and are subject to risks anduncertainties which may cause actual results to differ materially fromthose projected in a forward-looking statement. These risks anduncertainties include, the continuing growth of the cardiovascular andrespiratory markets, the Company's ability to maintain its compliancewith FDA regulations and standards without adversely affecting theCompany's manufacturing capability or ability to meet its productionrequirements or profit margins, changes in the regulatory environmentgoverning the Company's compliance with the FDA, PTO, tax andcompetition issues, the Company's ability to achieve regulatoryapprovals for its products under development in a timely manner, theeffect of conditions in the pharmaceutical industry and the economy ingeneral, as well as certain other risks. A more detailed discussion ofrisks attendant to the forward-looking statements included in thispress release are set forth in the "Forward-Looking Information:Certain Cautionary Statements" section of the Company's Annual Reporton Form 10-K for the year ended December 31, 2004, filed with theSecurities and Exchange Commission, and in other reports filed withthe SEC.